• Logo
  • SBMUJournals

Apoptosis markers of circulating leukocytes are associated with the clinical course of inflammatory bowel disease

Azade Amini Kadijani, Fariba Javadinia, Zahra Gholamrezaei, Alireza Mirzaei, Zeinab Khazaei koohpar, Hedieh Balaii, Shaghayegh Baradaran Ghavami, Zahra Gholamrezaei, Hamid Asadzadeh Aghdaei
47

Views

PDF

Abstract

.


Keywords

Inflammatory bowel diseases, Apoptosis, Remission, Flare-up, Biomarker

References

Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014;20(1):91.

Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369(9573):1641-57.

Darakhshan F, Khojeini EV, Balaii H, Naderi N, Firouzi F, Farnood A, et al. Epidemiology of Inflammatory Bowel Disease in Iran: A review of 803 cases. Gastroenterol Hepatol Bed Bench 2009;1(1).

Xavier R, Podolsky D. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448(7152):427-34.

Peppelenbosch M, Van Deventer S. T cell apoptosis and inflammatory bowel disease. Gut 2004;53(11):1556-8.

Sturm A. What is the role of apoptosis in the normal and inflamed intestine? Inflam Bowel Dis 2008;14:S113-S4.

Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005;115(1):66.

LÜgering A, Lebiedz P, Koch S, Kucharzik T. Apoptosis as a therapeutic tool in IBD? Ann N Y Acad Sci 2006;1072(1):62-77.

Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J 2018:2050640618774637.

Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016;22(3):1017.

Hanauer SB. Combination Therapy for Inflammatory Bowel Disease. Gastroenterol Hepatol 2017;13(5).

Mary J-Y, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30(7):983-9.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317(26):1625-9.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008;3(6):1101.

Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007;56(2):293-303.

Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012;61(8):1146-53.

Hagiwara C, Tanaka M, Kudo H. Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery. J Gastroenterol Hepatol 2002;17(7):758-64.

Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG, et al. Increased enterocyte apoptosis in inflamed areas of Crohn’s disease. Dis Colon Rectum 2003;46(11):1498-507.

Amini KA, Asadzadeh AH, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Translat Gastroenterol 2017;8(9):e117.

Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95(12):3452-7.

Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101(5):1163.

Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut 2004;53(1):70-7.

Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, et al. TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn’s disease. J Immunol 2006;176(4):2617-24.

Lügering A, Schmidt M, Lügering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121(5):1145-57.

Coury F, Ferraro-Peyret C, Le Cam S, Guerin S, Tebib J, Sibilia J, et al. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy. Clin Experiment Rheumatol 2008;26(2):234.

El-Hodhod M, Aly R, Youssef S, Mohamed S. Enhanced blood lymphocytes apoptosis in children with inflammatory bowel disease. ISRN gastroenterol 2013; doi: 10.1155/2013/415417




DOI: https://doi.org/10.22037/ghfbb.v0i0.1453